title: Addition of SRL 172 to standard chemotherapy in small cell lung cancer (SCLC) improves symptom control.
authors.forename: C L
authors.initials: CL
authors.lastname: Harper-Wynne
authors.forename: K
authors.initials: K
authors.lastname: Sumpter
authors.forename: C
authors.initials: C
authors.lastname: Ryan
authors.forename: K
authors.initials: K
authors.lastname: Priest
authors.forename: A
authors.initials: A
authors.lastname: Norton
authors.forename: P
authors.initials: P
authors.lastname: Ross
authors.forename: H E R
authors.initials: HE
authors.lastname: Ford
authors.forename: P
authors.initials: P
authors.lastname: Johnson
authors.forename: M E R
authors.initials: ME
authors.lastname: O'Brien
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001428:Bacterial Vaccines / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D018288:Carcinoma, Small Cell / Q000188:drug therapy*; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D009161:Mycobacterium; D016019:Survival Analysis
chemical_list: D001428:Bacterial Vaccines; C451081:SRL172